Abstract |
Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.
|
Authors | Takahiro Higuchi, Syoutoku Tagawa, Naohiro Yoshida, Tsutomu Araki, Taketsugu Tsuchiya, Koutarou Higashi, Junichi Taki, Seigo Kinuya, Kenichi Nakajima, Masatoshi Ikeda, Masanobu Namura, Norihisa Tonami |
Journal | Annals of nuclear medicine
(Ann Nucl Med)
Vol. 17
Issue 6
Pg. 499-501
(Sep 2003)
ISSN: 0914-7187 [Print] Japan |
PMID | 14575387
(Publication Type: Case Reports, Comparative Study, Journal Article)
|
Chemical References |
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
- Technetium Tc 99m Sestamibi
|
Topics |
- Adenocarcinoma, Bronchiolo-Alveolar
(diagnostic imaging, pathology)
- Aged
- Diagnosis, Differential
- False Negative Reactions
- Fluorodeoxyglucose F18
(pharmacokinetics)
- Humans
- Lung Neoplasms
(diagnostic imaging, pathology)
- Male
- Radiography
- Radionuclide Imaging
- Radiopharmaceuticals
(pharmacokinetics)
- Sensitivity and Specificity
- Technetium Tc 99m Sestamibi
(pharmacokinetics)
|